AI Insight
Three major studies demonstrate that finerenone, a kidney drug, provides protective benefits for both kidneys and heart in a much broader patient population than initially recognized. The drug significantly reduced kidney disease progression, kidney failure risk, heart failure, cardiovascular death, and overall mortality across multiple patient groups. Notably, benefits extended beyond diabetic patients to include those with non-diabetic kidney disease, a population that currently has few effective treatment options.
Why it matters
This finding could potentially expand treatment options for millions of patients with chronic kidney disease who previously had limited therapeutic choices, particularly those without diabetes. The dual protective effect on both kidneys and cardiovascular system addresses two interconnected health issues simultaneously, potentially improving outcomes and quality of life for a large patient population.
A trio of major studies found that finerenone may protect the kidneys and heart in far more people than previously thought. The drug significantly slowed kidney disease progression and reduced the risks of kidney failure, heart failure, cardiovascular death, and overall mortality. Researchers saw benefits not only in patients with diabetes but also in those with non-diabetic kidney disease, a group with limited treatment options.
Source: Doctors thought this kidney drug helped some patients. It may help millions more.